East China Medicine disclosed the semi -annual report of 2022, realizing net profit of 1.341 billion yuan

On August 9, 2022, East China Pharmaceutical (Code: 000963.SZ) released the 2022 semi -annual performance report.

From January 1, 2022-June 30, 2022, the company achieved operating income of 18.198 billion yuan, an increase of 5.93%year-on-year, and net profit was 1.341 billion yuan, an increase of 3.09%year-on-year, and the basic earnings per share were 0.77 yuan.

The company's industry is chemical pharmaceutical.

Among them, commercial income was 12.228 billion yuan, an increase of 3.93%year -on -year, and manufacturing revenue was 5.729 billion yuan, an increase of 2.31%year -on -year. 100 million yuan, a year-on-year increase of 92.19%, domestic medical beauty revenue was 413 million yuan, an increase of 263.50%year-on-year, and the income of offset (offset) -519 million yuan.

During the company's reporting period, the total assets at the end of the period were 28.761 billion yuan, the operating profit was 1.646 billion yuan, the accounts receivable were 7.454 billion yuan, and the net cash flow generated by operating activities was 284 million yuan. Cash was 18.859 billion yuan.

East China Pharmaceutical, the company's full name East China Pharmaceutical Co., Ltd., was established on March 31, 1993. The current general manager Lu Liang. Pharmaceutical research and development, production, and distribution.

- END -